Company intelligence / Profile preview

Forsight Vision

Menlo Park, California, United Statesforsightvisioncare.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company's lead product was a non-invasive periocular ring ("Helios insert") designed to deliver sustained-release medication for glaucoma and ocular hypertension. Clinical data showed long-term intraocular pressure reduction with improved patient compliance compared to traditional eye drops. The company was acquired by Allergan in August 2016 for $95 million upfront plus milestone payments.

Therapeutic areas: OphthalmologyImmunology
Modalities: DeviceSmall molecule
Industry: Implantable Medical Devices

Partnerships

No major pharma partnerships disclosed prior to Allergan acquisition.

Beyond the preview

Go deeper on Forsight Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forsight Vision.

Explore the full profile